Recent Advances in Adenovirus-Vectored Vaccines Development
DOI:
https://doi.org/10.17140/VROJ-2-e004Abstract
Recombinant adenovirus-vectored vaccines based on human adenovirus serotype 5 (HAdV-5) have been extensively studied both pre-clinically and in clinical trials for the past 25 years. Initially, they were considered as the most promising platform for human immunodeficiency virus (HIV) vaccine development. However, HAdV-5-based vaccine did not meet expectations in a large-scale clinical trial called STEP trial.1 In that trial, the vaccine not only showed lack of efficacy, but also suggested an increased trend for HIV acquisition in individuals with pre-existing HAdV-5 neutralizing antibodies.
Researches have developed vectors based on alternative serotypes of human and non-human adenoviruses in order to overcome challenges with HAd5-based vectors. To date, HAdV-35, HAdV-26 and simian adenoviruses ChAd3, ChAd63 and ChAdOx1 have been tested in several phase 1 clinical trials as candidate vaccine component against Mycobacterium tuberculosis, Plasmodium falciparum, HIV, Ebola, HCV and influenza virus. These vectors were chosen because most people have little or no immunity to them, and their biological characteristics, such as utilization of primary cellular receptor and elicitation of innate cytokine responses, differ from HAdV-5.
References
McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: A case-cohort analysis. Lancet. 2008; 372(9653): 1894-1905. doi: 10.1016/S0140-6736(08)61592-5
Havenga M, Vogels R, Zuijdgeest D, et al. Novel replication-incompetent adenoviral B-group vectors: High vector stability and yield in PER.C6 cells. J Gen Virol. 2006; 87(Pt 8): 2135-2143. doi: 10.1099/vir.0.81956-0
Abel B, Tameris M, Mansoor N, et al. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am J Respir Crit Care Med. 2010; 181(12): 1407-1417. doi: 10.1164/rccm.200910-1484OC
Hoft DF, Blazevic A, Stanley J, et al. A recombinant adenovirus expressing immunodominant TB antigens can significantly en-hance BCG-induced human immunity. Vaccine. 2012; 30(12): 2098-2108. doi: 10.1016/j.vaccine.2012.01.048
Tameris M, Hokey DA, Nduba V, et al. A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculo-sis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants. Vaccine. 2015; 33(25): 2944- 2954. doi: 10.1016/j.vaccine.2015.03.070
Creech CB, Dekker CL, Ho D, et al. Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adeno-virus type 35-based circumsporozoite malaria vaccine in healthy adults. Hum Vaccin Immunother. 2013; 9(12): 2548-2557. doi: 10.4161/hv.26038
Ouedraogo A, Tiono AB, Kargougou D, et al. A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evalu-ate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age. PLoS One. 2013; 8(11): e78679. doi: 10.1371/journal.pone.0078679
Baden LR, Karita E, Mutua G, et al. Assessment of the safety and immunogenicity of 2 novel vaccine platforms for HIV-1 preven-tion: A randomized trial. Ann Intern Med. 2016; 164(5): 313-322. doi: 10.7326/M15-0880
O’Hara GA, Duncan CJ, Ewer KJ, et al. Clinical assessment of a recombinant simian adenovirus ChAd63: A potent new vaccine vector. J Infect Dis. 2012; 205(5): 772-781. doi: 10.1093/infdis/jir850
Sheehy SH, Duncan CJ, Elias SC, et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: Assessment of efficacy against mosquito bite challenge in humans. Mol Ther. 2012; 20(12): 2355-2368. doi: 10.1038/mt.2012.223
Ogwang C, Afolabi M, Kimani D, et al. Safety and immunogenicity of heterologous prime-boost immunisation with Plasmo-dium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults. PLoS One. 2013; 8(3): e57726. doi: 10.1371/journal.pone.0057726
Barnes E, Folgori A, Capone S, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med. 2012; 4(115): 115ra111. doi: 10.1126/scitranslmed.3003155
Swadling L, Capone S, Antrobus RD, et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med. 2014; 6(261): 261ra153. doi: 10.1126/scitrans-lmed.3009185
Antrobus RD, Coughlan L, Berthoud TK, et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mol Ther. 2014; 22(3): 668-674. doi: 10.1038/mt.2013.284
Milligan ID, Gibani MM, Sewell R, et al. Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia ankara-vectored ebola vaccines: A randomized clinical trial. JAMA. 2016; 315(15): 1610-1623. doi: 10.1038/mt.2013.284
De Santis O, Audran R, Pothin E, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: A randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis. 2016; 16(3): 311- 320. doi: 10.1016/S1473-3099(15)00486-7
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Vaccination Research (VR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.